Mostrar el registro sencillo del ítem
| dc.contributor.author | Bishton, Mark | |
| dc.contributor.author | Marshall, Scott | |
| dc.contributor.author | Harchowal, Jatinder | |
| dc.contributor.author | Salles, Gilles | |
| dc.contributor.author | Golfier, Camille | |
| dc.contributor.author | Tucci, Alessandra | |
| dc.contributor.author | Rodríguez-Fernández, Alicia | |
| dc.contributor.author | Sánchez-Blanco, José-Javier | |
| dc.contributor.author | Bocchia, Mónica | |
| dc.contributor.author | Kim, SooKyoung | |
| dc.contributor.author | Lee, Young-Nam | |
| dc.contributor.author | Zinzani, Pier-Luigi | |
| dc.date.accessioned | 2025-11-18T09:28:14Z | |
| dc.date.available | 2025-11-18T09:28:14Z | |
| dc.date.issued | 2022-08 | |
| dc.identifier.citation | Bishton M, Marshall S, Harchowal J, Salles G, Golfier C, Tucci A, et al. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin¿s lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe. Hematological Oncology. agosto de 2022;40(3):370-80. | |
| dc.identifier.issn | 0278-0232 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/20750 | |
| dc.description.abstract | Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen (¿90 min) in clinical practice, published data on the safety of RI of CT-P10 in patients with NHL and CLL are limited. Hence, this study collected real-world safety and effectiveness data on RI-CT-P10 from the medical records of 196 patients with NHL or CLL in 10 European centers, 6 months after the date of the first RI (index date); the infusion-related reaction (IRR) rate was compared to previously published data. Ten percent (95% confidence interval 6%-15%; n = 20/196) of patients experienced an infusion-related reaction (IRR) on day 1-2 post-index, which was not significantly different (p = 0.45) to the IRR rate for rituximab described in a previous meta-analysis (8.8%). During the observation period, 2% of patients experienced grade 3-5 IRRs and 85% (n = 166) experienced an adverse event (non-IRR). The most common reason for discontinuation of first-line CT-P10 was planned treatment completion (81%; n = 158). Complete response and partial response to CT-P10 was observed in 74% (n = 142/192) and 22% (n = 42/192) of patients, respectively. The results of this real-world study demonstrate that the safety and effectiveness profile of RI-CT-P10 is similar to RI of reference rituximab and therefore support the current use of RI-CT-P10 in patients with NHL and CLL. | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.subject.mesh | Antibodies, Monoclonal, Murine-Derived | |
| dc.subject.mesh | Biosimilar Pharmaceuticals/adverse effects | |
| dc.subject.mesh | Drug-Related Side Effects and Adverse Reactions | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy | |
| dc.subject.mesh | Lymphoma, Non-Hodgkin/drug therapy | |
| dc.subject.mesh | Retrospective Studies | |
| dc.subject.mesh | Rituximab/adverse effects | |
| dc.subject.mesh | Treatment Outcome | |
| dc.title | The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 35168291 | |
| dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/10.1002/hon.2978 | |
| dc.identifier.doi | 10.1002/hon.2978 | |
| dc.journal.title | Hematological Oncology | |
| dc.identifier.essn | 1099-1069 |